174 related articles for article (PubMed ID: 23587956)
1. Drug combinations against Mucor irregularis in vitro.
Zhang S; Li R; Yu J
Antimicrob Agents Chemother; 2013 Jul; 57(7):3395-7. PubMed ID: 23587956
[TBL] [Abstract][Full Text] [Related]
2. In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis.
Cuenca-Estrella M; Gomez-Lopez A; Buitrago MJ; Mellado E; Garcia-Effron G; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2006 Jun; 50(6):2248-50. PubMed ID: 16723597
[TBL] [Abstract][Full Text] [Related]
3. A Revised Species Concept for Opportunistic
Wagner L; de Hoog S; Alastruey-Izquierdo A; Voigt K; Kurzai O; Walther G
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182532
[TBL] [Abstract][Full Text] [Related]
4. In vitro interaction of itraconazole with amphotericin B, caspofungin, and terbinafine against clinical isolates of Trichosporon asahii.
Li H; Qiao J; Wan Z; Zhang J
Mycopathologia; 2011 May; 171(5):345-8. PubMed ID: 21153882
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of nine antifungal drugs against 81 Phialophora and Cyphellophora isolates.
Feng P; Najafzadeh MJ; Sun J; Ahmed S; Xi L; de Hoog GS; Lai W; Lu C; Klaassen CH; Meis JF
Antimicrob Agents Chemother; 2012 Nov; 56(11):6044-7. PubMed ID: 22948876
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
Shi JY; Xu YC; Shi Y; Lü HX; Liu Y; Zhao WS; Chen DM; Xi LY; Zhou X; Wang H; Guo LN
Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of antifungal combinations against Candida albicans biofilms.
Tobudic S; Kratzer C; Lassnigg A; Graninger W; Presterl E
J Antimicrob Chemother; 2010 Feb; 65(2):271-4. PubMed ID: 19996142
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Interactions between Target of Rapamycin Kinase Inhibitor and Antifungal Agents against Aspergillus Species.
Gao L; Ding X; Liu Z; Wu Q; Zeng T; Sun Y
Antimicrob Agents Chemother; 2016 Jun; 60(6):3813-6. PubMed ID: 26976874
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of the type of interaction obtained by the combination of terbinafine and itraconazole, voriconazole, or amphotericin B against dematiaceous molds.
Biancalana FS; Lyra L; Schreiber AZ
Antimicrob Agents Chemother; 2011 Sep; 55(9):4485-7. PubMed ID: 21690288
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo susceptibility of two-drug and three-drug combinations of terbinafine, itraconazole, caspofungin, ibuprofen and fluvastatin against Pythium insidiosum.
Argenta JS; Alves SH; Silveira F; Maboni G; Zanette RA; Cavalheiro AS; Pereira PL; Pereira DI; Sallis ES; Pötter L; Santurio JM; Ferreiro L
Vet Microbiol; 2012 May; 157(1-2):137-42. PubMed ID: 22209120
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of a wide panel of antifungal drugs against various Scopulariopsis and Microascus species.
Skóra M; Bulanda M; Jagielski T
Antimicrob Agents Chemother; 2015 Sep; 59(9):5827-9. PubMed ID: 26100698
[TBL] [Abstract][Full Text] [Related]
12. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.
Cuenca-Estrella M; Gomez-Lopez A; Garcia-Effron G; Alcazar-Fuoli L; Mellado E; Buitrago MJ; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2005 Mar; 49(3):1232-5. PubMed ID: 15728937
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
Pastor FJ; Ruíz-Cendoya M; Pujol I; Mayayo E; Sutton DA; Guarro J
Antimicrob Agents Chemother; 2010 Nov; 54(11):4550-5. PubMed ID: 20805397
[TBL] [Abstract][Full Text] [Related]
14. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species.
Ryder NS; Leitner I
Med Mycol; 2001 Feb; 39(1):91-5. PubMed ID: 11270414
[TBL] [Abstract][Full Text] [Related]
15. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.
Diekema DJ; Messer SA; Hollis RJ; Jones RN; Pfaller MA
J Clin Microbiol; 2003 Aug; 41(8):3623-6. PubMed ID: 12904365
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
[TBL] [Abstract][Full Text] [Related]
17. In vitro antifungal susceptibility of Cladophialophora carrionii, an agent of human chromoblastomycosis.
Deng S; de Hoog GS; Badali H; Yang L; Najafzadeh MJ; Pan B; Curfs-Breuker I; Meis JF; Liao W
Antimicrob Agents Chemother; 2013 Apr; 57(4):1974-7. PubMed ID: 23380718
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of eight antifungal drugs against 106 waterborne and cutaneous exophiala species.
Najafzadeh MJ; Saradeghi Keisari M; Vicente VA; Feng P; Shamsian SA; Rezaei-Matehkolaei A; de Hoog GS; Curfs-Breuker I; Meis JF
Antimicrob Agents Chemother; 2013 Dec; 57(12):6395-8. PubMed ID: 24100491
[TBL] [Abstract][Full Text] [Related]
19. Large-Scale Evaluation of
Thompson GR; Barker BM; Wiederhold NP
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096163
[TBL] [Abstract][Full Text] [Related]
20. In vitro synergy of caspofungin with licensed and novel antifungal drugs against clinical isolates of Fusarium spp.
Shalit I; Shadkchan Y; Mircus G; Osherov N
Med Mycol; 2009; 47(5):457-62. PubMed ID: 18720217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
